178 related articles for article (PubMed ID: 2659565)
21. The spectrum of Escherichia coli--Bacteroides fragilis pathogenic synergy in an intraabdominal infection model.
Rotstein OD; Kao J
Can J Microbiol; 1988 Mar; 34(3):352-7. PubMed ID: 3046726
[TBL] [Abstract][Full Text] [Related]
22. Reciprocal synergy between Escherichia coli and Bacteroides fragilis in an intra-abdominal infection model.
Rotstein OD; Kao J; Houston K
J Med Microbiol; 1989 Aug; 29(4):269-76. PubMed ID: 2668529
[TBL] [Abstract][Full Text] [Related]
23. In-vivo bactericidal activity of Sch 34343 in Bacteroides fragilis abscesses and in Bacteroides fragilis-Escherichia coli abscesses.
Wells CL; Arland LA; Simmons RL; Rotstein OD
J Antimicrob Chemother; 1985 Jun; 15 Suppl C():199-206. PubMed ID: 3897172
[TBL] [Abstract][Full Text] [Related]
24. Combined activity of metronidazole and gentamicin on Bacteroides fragilis in vivo and in vitro.
Dijkmans BA; Vaishnav J; Mattie H
J Antimicrob Chemother; 1985 Jan; 15(1):77-82. PubMed ID: 3882656
[TBL] [Abstract][Full Text] [Related]
25. Lethal microbial synergism in intra-abdominal infections. Escherichia coli and Bacteroides fragilis.
Rotstein OD; Pruett TL; Simmons RL
Arch Surg; 1985 Feb; 120(2):146-51. PubMed ID: 3156575
[TBL] [Abstract][Full Text] [Related]
26. [In vitro and in vivo antimicrobial activities of cefmetazole against Bacteroides fragilis].
Isono M; Kawashima K; Yamada N; Aoki M; Kobayashi T; Sawa K; Watanabe K; Ueno K
Jpn J Antibiot; 1982 Jul; 35(7):1667-72. PubMed ID: 6757469
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of amoxycillin/clavulanic acid in experimental Bacteroides fragilis/Escherichia coli mixed infections.
Beale AS; Gisby J; Sutherland R
J Antimicrob Chemother; 1988 Apr; 21(4):451-9. PubMed ID: 3288604
[TBL] [Abstract][Full Text] [Related]
28. Fibrin in peritonitis. IV. Synergistic intraperitoneal infection caused by Escherichia coli and Bacteroides fragilis within fibrin clots.
Dunn DL; Rotstein OD; Simmons RL
Arch Surg; 1984 Feb; 119(2):139-44. PubMed ID: 6365029
[TBL] [Abstract][Full Text] [Related]
29. Comparative efficacy of ceftriaxone in experimental infections involving Bacteroides fragilis and Escherichia coli.
Dezfulian M; Bitar RA; Bartlett JG
Chemotherapy; 1993; 39(5):355-60. PubMed ID: 8370326
[TBL] [Abstract][Full Text] [Related]
30. In vitro bactericidal activities and morphologic changes in Escherichia coli and Bacteroides fragilis by cephalosporins.
Mikamo H; Kawazoe K; Sato Y; Hayasaki Y; Satoh M; Kai J; Tamaya T
Chemotherapy; 1998; 44(3):157-63. PubMed ID: 9612605
[TBL] [Abstract][Full Text] [Related]
31. The role of Bacteroides encapsulation in the lethal synergy between Escherichia coli and Bacteroides species studied in a rat fibrin clot peritonitis model.
Rotstein OD; Pruett TL; Wells CL; Simmons RL
J Infect; 1987 Sep; 15(2):135-46. PubMed ID: 3312420
[TBL] [Abstract][Full Text] [Related]
32. Early events after intra-abdominal infection with Bacteroides fragilis and Escherichia coli.
Verweij WR; Namavar F; Schouten WF; MacLaren DM
J Med Microbiol; 1991 Jul; 35(1):18-22. PubMed ID: 2072375
[TBL] [Abstract][Full Text] [Related]
33. In vivo efficacy of trovafloxacin against Bacteroides fragilis in mixed infection with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium in an established-abscess murine model.
Stearne LE; Gyssens IC; Goessens WH; Mouton JW; Oyen WJ; van der Meer JW; Verbrugh HA
Antimicrob Agents Chemother; 2001 May; 45(5):1394-401. PubMed ID: 11302801
[TBL] [Abstract][Full Text] [Related]
34. Quantification of the effect of anti-anaerobic drugs in experimental Bacteroides fragilis infection in mice.
Dijkmans BA; Mattie H; Hermans J; van Furth R
J Antimicrob Chemother; 1984 Jan; 13(1):79-86. PubMed ID: 6365877
[TBL] [Abstract][Full Text] [Related]
35. Therapeutic efficacy and pharmacokinetic properties of ciprofloxacin in intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli.
Fu KP; Vince T; Bloom R; Gregory FJ; Hung PP
Drugs Exp Clin Res; 1987; 13(8):493-6. PubMed ID: 3322752
[TBL] [Abstract][Full Text] [Related]
36. Effects of Escherichia coli and Bacteroides fragilis on peritoneal host defenses.
Dunn DL; Barke RA; Ewald DC; Simmons RL
Infect Immun; 1985 May; 48(2):287-91. PubMed ID: 3886544
[TBL] [Abstract][Full Text] [Related]
37. Comparative activities of aztreonam and cefotaxime against Escherichia coli and Bacteroides spp. in pure and mixed cultures.
Soriano F; Ponte MC
Antimicrob Agents Chemother; 1984 Jul; 26(1):39-41. PubMed ID: 6089653
[TBL] [Abstract][Full Text] [Related]
38. Synergistic lethality in experimental infections with Escherichia coli and Bacteroides fragilis.
Rodloff AC; Hahn H
Zentralbl Bakteriol Mikrobiol Hyg A; 1984 Oct; 258(1):112-9. PubMed ID: 6395577
[TBL] [Abstract][Full Text] [Related]
39. Synergy of Bacteroides fragilis and Escherichia coli in the induction of KC gene expression in mouse peritoneal tissues.
Kim JM; Kim YJ; Cho YJ
Scand J Infect Dis; 2000; 32(6):643-9. PubMed ID: 11200375
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of amoxycillin and benzylpenicillin combined with clavulanic acid against Bacteroides fragilis in vitro and in experimentally infected mice.
Dijkmans BA; Vaishnav J; Mattie H
Scand J Infect Dis; 1985; 17(3):311-21. PubMed ID: 3903976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
